Remote Monitoring Cuts Clinic Visits in Half Without Compromising Blood Sugar Control

Researchers followed 109 people with Type 1 diabetes who use the MiniMed 780G automated insulin delivery system. Instead of scheduling multiple in-person clinic visits each year, participants switched to a new care model: one combined visit with their doctor and diabetes nurse per year, supported by remote monitoring through CareLink Premium—a digital platform that tracks insulin pump data.

The study compared outcomes during a 12-month period before the change with a 12-month period after implementation.

After implementing telemonitoring-supported care, outpatient visits dropped from an average of 4.92 visits per person per year to 2.49 visits—roughly a 50% reduction.

Despite seeing their healthcare team less often in person, participants' blood sugar control remained stable. HbA1c—a measure of average blood sugar over three months—stayed essentially unchanged (56.3 before versus 56.2 after). Time in range, which reflects how many hours per day blood sugars stay within target, also remained steady at around 72–75%.

The researchers found no safety signals or increase in serious adverse events. During both the year before and the year after the change, one diabetic ketoacidosis (DKA) event occurred, with no additional safety concerns identified.

Patient satisfaction actually improved under the new model. Participants reported high satisfaction with the telemonitoring-supported care approach and with using digital messaging to communicate with their care team. Treatment satisfaction scores increased, reflecting that people felt supported even with fewer clinic visits.

This real-world evidence suggests that for people using modern automated insulin pumps with good remote monitoring tools, switching from frequent in-person visits to annual in-person appointments plus structured telemonitoring is feasible. The approach maintained blood sugar control and safety while reducing burden on both patients and healthcare systems.

The findings don't mean that everyone with Type 1 diabetes can follow this exact model—needs vary widely. However, the study offers encouraging evidence that telemonitoring can be part of a sustainable care redesign that works for some individuals, especially those using automated delivery systems that generate detailed digital data.

Source: Metabolic syndrome and related disorders. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.